Fresh analysis indicates that people who come off blockbuster weight-loss injections like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise programs.
Research printed in a major medical journal demonstrates that while obese people often shed about a fifth of their total mass while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month after stopping.
"People using such medications should be cognizant of the danger of quick rebound weight gain when the treatment is stopped," warns expert Dr. Susan Jebb.
This pace of recovery implies a reversion to starting mass in about 18 months.
Weighing Approaches
The study, which looked at 37 of studies involving thousands of patients, compared the outcomes of these new drugs with older methods.
Researchers note that people who lose weight through dieting usually experience a less rapid creep back—around 100 grams monthly—post-intervention.
Understanding the Quick Rebound
Nutrition scientists believe the mechanism of the injections accounts for the accelerated rebound.
GLP-1 drugs copy a body's own chemical called GLP-1, which helps regulate appetite.
"Sustained high doses of GLP-1 levels far above than normal may cause the system to produce less of its endogenous hormone, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' results in hunger is no longer kept in check, making overeating a significant risk."
A Lifelong Condition?
Health authorities recommend the jabs for people with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
Professionals argue that, given the significant potential of relapse, the treatment is often life-long.
This view is reinforced by drug manufacturers, who note that the results "underscore the long-term nature of excess weight," comparing it to managing diseases like high blood pressure.
User Testimonies
People who have discontinued the medication explain a sudden return of hunger.
"It felt as if a trigger that goes on and you become ravenous," described one woman.
This difficulty is compounded if individuals have not established lasting dietary or behavioural changes during treatment.
Significant Use
Survey data show that millions of adults in the UK have used these injections in the last 12 months, with interest continuing to grow.
- Adoption is more common among females compared to males.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
Ultimately, researchers emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a permanent cure and lasting health benefits relies on ongoing lifestyle support.
